Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.
Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.